Journal
NATURE REVIEWS NEUROSCIENCE
Volume 16, Issue 12, Pages 705-718Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrn4036
Keywords
-
Categories
Funding
- German Research Foundation [SFB TRR 58, CRC 1080, FOR 926]
- Institut national de la sante et de la recherche medicale (INSERM)
- European Commission Seventh Framework Programme (REPROBESITY) [HEALTH-F2-2008-223713]
- European Commission Seventh Framework Programme (PAINCAGE)
- European Commission Seventh Framework Programme [HEALTH-2014-603191]
- European Research Council (Endofood) [ERC-2010-StG-260515]
- European Research Council (CannaPreg)
- European Research Council [ERC-2014-PoC-640923]
- Fondation pour la Recherche Medicale [DRM20101220445]
- Human Frontiers Science Program
- Agence Nationale de la Recherche [ANR Blanc NeuroNutriSens ANR-13-BSV4-0006, BRAIN ANR-10-LABX-0043]
- grant RETICS-RTA [RD12/0028/0023]
- grant AGAUR [2014-SGR-1547]
- US National Institutes of Health [DA038663, DA026996, MH102838]
- Region Aquitaine
- [SAF2014-59648P]
- [Health-F2-2013-602891]
Ask authors/readers for more resources
The endocannabinoid (eCB) system has emerged as a central integrator linking the perception of external and internal stimuli to distinct neurophysiological and behavioural outcomes (such as fear reaction, anxiety and stress-coping), thus allowing an organism to adapt to its changing environment. eCB signalling seems to determine the value of fear-evoking stimuli and to tune appropriate behavioural responses, which are essential for the organism's long-term viability, homeostasis and stress resilience; and dysregulation of eCB signalling can lead to psychiatric disorders. An understanding of the underlying neural cell populations and cellular processes enables the development of therapeutic strategies to mitigate behavioural maladaptation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available